However, to provide a solid theoretical basis for the development of new drugs for ccRCC treatment, further research is needed to clarify the specific mechanisms by which FDX1 regulates FMR1 and the effects of FMR1 on its downstream pathways, including ALCAM. The gene discussed is FDX1; the disease is nonpapillary renal cell carcinoma.